- Home
- LSPD vs OGN Comparison
LSPD vs OGN Comparison
Compare LSPD & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSPD | OGN |
|---|---|---|
| Founded | 2005 | 1923 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LSPD | OGN |
|---|---|---|
| Price | $12.47 | $8.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 5 |
| Target Price | $13.63 | ★ $14.10 |
| AVG Volume (30 Days) | 438.6K | ★ 4.9M |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.99% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.91 |
| Revenue | $1,157,458,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | $15.25 | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | ★ N/A | $4.21 |
| Revenue Growth | ★ 14.24 | N/A |
| 52 Week Low | $7.34 | $6.18 |
| 52 Week High | $15.22 | $17.23 |
Technical Indicators
Market Signals| Indicator | LSPD | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 67.29 |
| Support Level | $11.96 | $7.90 |
| Resistance Level | $12.59 | $8.49 |
| Average True Range (ATR) | 0.35 | 0.30 |
| MACD | 0.02 | 0.14 |
| Stochastic Oscillator | 87.06 | 80.59 |
Price Performance
Historical ComparisonAbout LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.